Figure 3From: Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)Percent change in total cholesterol, HDL-C and triglycerides after 6 weeks of treatment.Back to article page